Scholarlink

<p>The results from DESTINY-Breast 04 and the subsequent introduction of trastuzumab-deruxtecan as a potential treatement for HER2-low breast cancer necessitated the reevaluation of HER2 scoring. The discordance in HER2 scoring reported in previous studies led us to initiate a regional ring study and to assess our data. This ring study involved 61 breast pathology experts from four countries across the Balkans region. The research comprised 20 samples, including biopsies and surgical specimens, sourced from the archives of one institution. We amassed a total of 1220 scores. The findings indicate a significant degree of interobserver agreement among pathologists in scoring individual categories (scores 0, 1+, 2+, and 3+), with even higher agreement observed when scores 1 + and 2 + were combined into a single, HER2-low category. The findings of this study indicate that adequate education, awareness regarding the therapeutic significance of the HER2-low category, and expertise in breast pathology facilitate the accurate identification of HER2-low breast cancers. These findings will promote ongoing training in breast pathology within the region and will provide a reference for subsequent research efforts.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Concordance of HER2-low scoring in breast carcinomas among pathologists

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月9日

查看全文
  • Snježana Tomić,
  • Tatjana Kapicl Ivković,
  • Marija Milković Periša,
  • Duško Đunđerović,
  • Maja Jovičić Milentijević,
  • Svetlana Oprić,
  • Slobodanka Mitrović,
  • Irena Jovanić,
  • Savelina Popovska,
  • Svitlana Bachurska,
  • Desislava Tashkova,
  • Kalin Kalchev,
  • Ljiljana Vučković,
  • Manuela Avirović,
  • Emina Babarović,
  • Melita Perić Balja,
  • Čedna Tomasović-Lončarić,
  • Jasmina Rajc,
  • Irena Zagorac,
  • Davor Oršolić,
  • Toni Čeprnja

摘要

The results from DESTINY-Breast 04 and the subsequent introduction of trastuzumab-deruxtecan as a potential treatement for HER2-low breast cancer necessitated the reevaluation of HER2 scoring. The discordance in HER2 scoring reported in previous studies led us to initiate a regional ring study and to assess our data. This ring study involved 61 breast pathology experts from four countries across the Balkans region. The research comprised 20 samples, including biopsies and surgical specimens, sourced from the archives of one institution. We amassed a total of 1220 scores. The findings indicate a significant degree of interobserver agreement among pathologists in scoring individual categories (scores 0, 1+, 2+, and 3+), with even higher agreement observed when scores 1 + and 2 + were combined into a single, HER2-low category. The findings of this study indicate that adequate education, awareness regarding the therapeutic significance of the HER2-low category, and expertise in breast pathology facilitate the accurate identification of HER2-low breast cancers. These findings will promote ongoing training in breast pathology within the region and will provide a reference for subsequent research efforts.